Literature DB >> 34556845

Value-based pricing of drugs with multiple indications or in combinations - lessons from Europe.

Kerstin N Vokinger1,2, Aaron S Kesselheim3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34556845     DOI: 10.1038/s41571-021-00561-6

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe.

Authors:  Kerstin N Vokinger; Thomas J Hwang; Paola Daniore; ChangWon C Lee; Ariadna Tibau; Thomas Grischott; Thomas J Rosemann; Aaron S Kesselheim
Journal:  JAMA Oncol       Date:  2021-09-16       Impact factor: 33.006

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.